Jacobs Journal for Gastroenterology and Hepatology
Articles in Press
Volume 2 Issue 4
Biliary Cystadenoma – A Literature Review
Biliary cystadenoma (BCA) is a pre-malignant, unilocular or multilocular cystic disease of liver, presenting commonly in middle-aged women with the mean age of 50 (range 38 – 64) years. It accounts for 5% of all cystic disease of liver. Differential diagnosis varies from simple liver cysts to cystic liver metastases. Aetiology of this lesion is unclear, but congenital and acquired theories have been proposed. It has variable size with smooth surface and internal septations. Some BCAs presents with nodules and/or papillary excrescence. Ovarian stroma is a striking feature, but BCAs without ovarian stroma have been reported. Clinical symptoms vary from vague abdominal pain to obstructive jaundice.
Dilated Stomach in Outlet Obstruction as a Cause of Small Bowel Volvulus: First Case Report
Aswini K Pujahari*
Small Bowel Volvulus (SBV) is rarely seen among adults. It becomes a surgical emergency. There is no single specific diagnostic clinical sign or abnormality in laboratoryor radiological findings. No role of conservative management in suspected case of SBV and early laparotomy should be done to avoid massive bowel resection due to gangrene. Benign gastric outlet obstruction (GOO) causing SBV is not yet reported so far.
Can we Restart Vemurafenib after Severe Hepatotoxicity? A Case Report
Eda Tanrıkulu Şimşek*, Mehmet Beşiroglu, Bilge Aktaş, Sinan Koca, Süleyman Halil, Özkan Alan, Rahip Hasanov, Nalan Akgül Babacan,Mehmet Akif Öztürk, Serap Kaya, Osman Cavit Ozdogan, Faysal Dane, Perran Fulden Yumuk
Advanced melanoma is a highly aggressive tumor with low response rate to the majority of cytotoxics. Currently, Vemurafenib is the treatment of choice for patients with BRAF mutant melanoma. It is generally safe and a well-tolerated drug and severe hepatotoxicity is rarely reported. This case reports our clinical experience of grade 4 hepatotoxicity related with Vemurafenib, which was successfully treated with steroids and restart of Vemurafenib under steroid therapy.